10-Q: Semnur Pharmaceuticals Reports Q3 Losses Amid SPAC Merger & Funding Delays

Semnur Pharmaceuticals, Inc. reported significant operating losses and negative cash flows for Q3 2025, following its business combination and facing delays in anticipated capital raises.

Summary

• The company consummated a business combination on September 22, 2025, with Denali Capital Acquisition Corp., which changed its name to Semnur Pharmaceuticals, Inc., and Legacy Semnur became a wholly-owned subsidiary.
• Net loss for the nine months ended September 30, 2025, was $(154.3) million, a significant increase from $(3.9) million for the same period in 2024.
• Cash and cash equivalents were critically low at $0.1 million as of September 30, 2025, down from $12 thousand at the beginning of the period.
• The accumulated deficit increased substantially to $(269.6) million as of September 30, 2025.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least one year after the financial statements' issuance date.
• Two significant capital raises, a PIPE SPA for $20.0 million and a Semnur/Biconomy SPA for $100.0 million (payable in Bitcoin), have not closed as of September 30, 2025, and have a termination option if not closed by December 31, 2025.
• The company's lead product candidate, SP-102 (SEMDEXA), a non-opioid pain management product for sciatica, has completed one pivotal Phase 3 study and initiated a second Phase 3 study in September 2025.
• SP-102 has been granted fast track designation by the FDA, but the FDA requested a confirmatory trial, indicating prior data was insufficient to support a 505(b)(2) New Drug Application (NDA) submission.
• General and administrative expenses for the three months ended September 30, 2025, increased by $150.4 million, primarily due to $140.0 million in consulting expense for shares issued at closing and $9.9 million in expensed deferred offering costs related to the Business Combination.
• The company identified material weaknesses in internal control over financial reporting related to the preparation of carve-out financial statements and stock-based compensation expense, with remediation efforts underway.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, a substantial increase in net loss, and a formal going concern warning. While its lead product candidate, SP-102, is in late-stage development and has fast-track designation, the FDA's request for a confirmatory trial and the failure of two critical capital raises to close by the reporting date create significant financial and operational uncertainty. The high G&A expenses related to the business combination further exacerbate the financial strain.

Positives

• Successfully completed a pivotal Phase 3 study for SP-102, achieving primary and secondary endpoints, with results published in PAIN Journal.
• Initiated a second Phase 3 study for SP-102 in September 2025, demonstrating continued product development.
• SP-102 received fast track designation from the FDA, potentially expediting development and review.
• Completed a business combination, leading to the company's securities trading on the OTCQB marketplace under new symbols SMNR and SMNRW.
• Total liabilities decreased from $49.468 million as of December 31, 2024, to $15.367 million as of September 30, 2025, largely due to the conversion of related party debt into preferred and common stock.

Negatives

• Reported a substantial net loss of $(154.3) million for the nine months ended September 30, 2025, significantly higher than $(3.9) million for the same period in 2024.
• Cash and cash equivalents are critically low at $0.1 million as of September 30, 2025.
• The accumulated deficit has grown to $(269.6) million, indicating significant historical losses.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Two anticipated capital raises, totaling $120.0 million (PIPE SPA for $20.0 million and Semnur/Biconomy SPA for $100.0 million), have not closed as of September 30, 2025, and face a termination deadline of December 31, 2025.
• The FDA requested a confirmatory Phase 3 trial for SP-102, indicating that the data from the initial trial was insufficient, which will delay the NDA filing and potential approval.
• General and administrative expenses surged by $150.4 million for the three months ended September 30, 2025, primarily due to $140.0 million in consulting expense for shares issued and $9.9 million in expensed deferred offering costs related to the business combination.
• Identified material weaknesses in internal control over financial reporting related to carve-out financial statements and stock-based compensation expense.
• The company has only one product candidate (SP-102) and has not generated any revenue from product sales to date.

Risks

• The company has a limited operating history and has incurred significant losses since inception, with anticipated continued losses for the foreseeable future.
• Sole dependence on SP-102; no products approved for commercial sale and no revenue from product sales to date, with no guarantee of future profitability.
• Substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and substantial cumulative net losses.
• Reliance on sole or single-source suppliers and manufacturers for SP-102 and its raw materials, with risks of disruption or inability to find alternatives.
• Reliance on third parties to conduct clinical trials, posing risks of non-compliance, delays, or failure to meet deadlines.
• Delays in clinical trials could result in increased costs and delay regulatory approval and revenue generation.
• Uncertainty of obtaining regulatory approval for SP-102, with potential for narrower indications or costly post-marketing requirements.
• Difficulty in enrolling or maintaining patients in clinical trials, which could cause delays or termination.
• Market opportunities for product candidates may be smaller than estimated, adversely affecting revenue and profitability.
• Significant competition in the biopharmaceutical and pain management industries from larger, better-resourced companies.
• Uncertainty regarding third-party payor coverage and adequate reimbursement for SP-102, if approved, potentially limiting market acceptance and revenue.
• Results of preclinical studies and early clinical trials may not be predictive of future clinical trial success, and interim data may change.
• SP-102 is complex and difficult to manufacture, leading to potential delays or supply problems.
• Inability to retain key executives could delay development efforts and harm the business.
• Exposure to product liability lawsuits, which could result in substantial liabilities or limit commercialization.
• Risks related to intellectual property, including inability to maintain patent protection, challenges to validity, infringement claims, and trade secret disclosure.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable, with potential for changes in policies or data requirements.
• The FDA may not conclude that SP-102 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, leading to longer development times and higher costs.
• Approved products will be subject to ongoing and continued regulatory requirements, which may result in significant expense and limit commercialization.
• Changes in FDA funding or policies could hinder timely review and approval of products.
• Failure to comply with health and data protection laws and regulations (e.g., HIPAA, CCPA, GDPR) could lead to penalties and reputational harm.
• The business may be impacted by actions of the new Trump administration, including executive orders, policies, new legislation, and judicial decisions.
• Risks related to the use of hazardous materials and compliance with environmental laws and regulations.
• Risk of misconduct by employees, independent contractors, consultants, commercial partners, and vendors, including non-compliance with regulatory standards.
• Potential conflicts of interest due to overlapping directors and officers with Scilex Holding Company.
• Financial statements may not be indicative of standalone operations, and the company will incur incremental costs as a standalone public company.
• Control by Scilex, whose interests may differ from those of public shareholders, and preferential rights of Series A Preferred Stock held by Scilex.
• Market price volatility of common stock due to various factors, including operating performance, clinical trial results, regulatory decisions, and general market conditions.
• Future sales of a substantial number of common shares (e.g., from warrants, consultant shares) may cause the stock price to decline.
• Warrants may never be in the money, may expire worthless, or their terms may be amended adversely.
• Risks related to the cryptocurrency treasury strategy, including high volatility of Bitcoin, untested strategy, potential classification of digital assets as securities, lack of legal recourse/insurance, and irreversibility of transactions.
• Anti-takeover provisions in the Charter and Bylaws and under Delaware law could make an acquisition more difficult.
• The Charter designates specific exclusive forums for certain litigation, potentially limiting stockholders' ability to choose a favorable judicial forum.
• As an emerging growth company, reduced reporting requirements may make common stock less attractive to investors.
• As a controlled company, the company may rely on exemptions from certain corporate governance requirements.
• Increased costs and management time required for public company compliance, including Sarbanes-Oxley Act requirements.
• Inability to satisfy initial or continued listing requirements of Nasdaq.
• Comprehensive U.S. federal income tax reform could adversely affect the company.
• Ability to use net operating loss and tax credit carryforwards may be subject to limitation due to ownership changes.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it continues to develop SP-102 and seek regulatory approval, with an estimated commercial launch in 2027. It will need additional financing to fund ongoing activities and is exploring various alternatives including equity offerings, debt financings, collaborations, and other capital sources. The company also plans to increase its full-time employees to build out its commercial infrastructure and other business functions as it transitions from reliance on Scilex.

Management Comments

• "Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions."
• "Through rigorous research and development, we believe we are on the cusp of establishing Semnur as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies."
• "We believe that we have made substantial progress in demonstrating the rapid onset and enhanced tolerability of our product candidate."
• "Management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the condensed consolidated financial statements are issued."

Industry Context

The company operates in the highly competitive biopharmaceutical and pain management industries, focusing on non-opioid solutions. Its lead product candidate, SP-102, aims to be the first FDA-approved epidural injection for sciatica, a condition affecting over 4.8 million patients in the U.S. by 2024. The industry is characterized by intense competition, rapid technological advances, and substantial upfront capital expenditures for product development. The regulatory landscape is complex and evolving, with new requirements for clinical trials and potential impacts from recent judicial decisions. The company's adoption of a cryptocurrency treasury strategy introduces novel risks associated with the volatile and uncertain digital asset industry.

Corporate Governance

Legal Proceedings

• As of September 30, 2025, the company was not a party to any material legal proceedings with respect to itself or any of its material properties.

Related Party Transactions

• Scilex Holding Company (Scilex) provided services and funding to support the company's operations.
• Related party indebtedness of $54.2 million owed to Scilex was converted into 5,423,606 shares of Series A Preferred Stock and 542,361 shares of Common Stock at the closing of the Business Combination.
• Loans from Scilex for stock-based compensation and expenses paid on behalf of the company totaled $10.314 million for the nine months ended September 30, 2025.
• A Transition Services Agreement was entered into with Scilex on September 22, 2025, for Scilex to provide various business functions on a cost-plus-10% basis, capped at $2.0 million per annum until the Scilex-Oramed Note is paid.
• Scilex controls approximately 87.5% of the company's voting power and holds Series A Preferred Stock with preferential rights.
• The Executive Chairman (Henry Ji, Ph.D.) and Chief Financial Officer (Stephen Ma) hold executive officer positions at both Semnur and Scilex, creating potential conflicts of interest.
• Legacy Semnur entered into an Assignment Agreement with Shah Investor LP on August 6, 2013, agreeing to pay royalties (1.5% up to $250.0 million in annual net sales, 2.5% above) for assigned intellectual property; no payments have been triggered to date.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity offerings and the exercise of warrants and options, as well as potential loss of investment due to the going concern risk and market price volatility.
• Employees may see increased hiring as the company builds standalone functions, but also face intense competition for talent and potential impacts from management's focus on financial stability.
• Customers and patients could benefit from a new non-opioid pain management product (SP-102) if approved, but delays in regulatory approval could impact access.
• Creditors holding promissory notes face repayment risk given the company's liquidity issues and going concern warning, with acceleration clauses tied to new financing.
• Suppliers and partners, particularly contract manufacturers like Lifecore, are critical to product development, and any disruptions could impact the company's ability to advance SP-102.

Next Steps

• Complete the second Phase 3 study for SP-102.
• Obtain additional financing through equity offerings, debt financings, collaborations, government contracts, or other capital sources.
• Close the PIPE SPA ($20.0 million) and Semnur/Biconomy SPA ($100.0 million in Bitcoin) by December 31, 2025.
• Address material weaknesses in internal control over financial reporting by implementing additional controls and hiring personnel.
• Develop commercial infrastructure and other business functions as the company transitions from reliance on Scilex.
• Seek regulatory approval for SP-102, with an estimated commercial launch in 2027.
• Manage and pay promissory notes totaling $4.5 million due within a year.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by critically low cash reserves ($0.1 million), a substantial accumulated deficit ($269.6 million), and a formal 'going concern' warning from management. The failure of two significant capital raises totaling $120.0 million to close by the reporting date, coupled with a December 31, 2025, termination deadline, creates immediate and profound liquidity risk. While the lead product candidate, SP-102, is in late-stage development and has fast-track designation, the FDA's request for a confirmatory trial introduces further delays and uncertainty in its path to market. The high general and administrative expenses incurred during the business combination, along with identified material weaknesses in internal controls, underscore operational challenges. Given the high degree of risk, immediate liquidity concerns, and significant uncertainty surrounding future funding and product approval, a seasoned investor would likely recommend selling the stock.

Keywords

Biopharmaceutical, Non-opioid pain management, SP-102, SEMDEXA, Sciatica, Clinical trials, FDA approval, Reverse recapitalization, SPAC, Going concern, Capital raise, Bitcoin, Cryptocurrency, Scilex, Corporate governance, Intellectual property, SEC filing, 10-Q